Bloomberg News reports:
Merck & Co. and its partner Ridgeback Biotherapeutics LP sought emergency use authorization in the U.S. for molnupiravir, moving the pill closer to becoming the first oral antiviral treatment for Covid-19.
An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization, the companies said in a statement Monday.
Submissions to regulatory authorities worldwide are expected in the coming months after interim analysis of clinical trial data found that it cut the risk of hospitalization for such patients by half.
Read the full article.
Merck seeks FDA emergency use authorization for molnupiravir, an experimental antiviral pill to treat Covid-19https://t.co/TMElQnZkom
— CNN Breaking News (@cnnbrk) October 11, 2021